Vacunas

Oberhardt, V., Luxenburger, H., Kemming, J. et al. Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine. Nature (2021). https://doi.org/10.1038/s41586-021-03841-4 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 28/07/2021 Abstract SARS-CoV-2 spike mRNA vaccines1–3 mediate protection from severe disease as early as 10 days post prime vaccination3, when neutralizing […]

Manish Sadarangani, Arnaud Marchant and Tobias R. Kollmann. Nature Reviews | Immunology Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 26/07/2021 Abstract Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including mRNA, adenoviral-vectored, protein subunit

Ikegame, S., Siddiquey, M.N.A., Hung, CT. et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 12, 4598 (2021). https://doi.org/10.1038/s41467-021-24909-9 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 26/07/2021 Abstract Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected at least 180 million people since its identification as

Amanda M. Craig, et al. DOI:https://doi.org/10.1016/j.ajogmf.2020.100295 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 25/07/2021 As of December 1, 2020, nearly 64 million people have been infected with the severe acute respiratory syndrome coronavirus 2 worldwide with nearly 1.5 million global deaths. The impact of this virus

Andrés H. Rossi et al. https://doi.org/10.1016/j.xcrm.2021.100359 (https://www.sciencedirect.com/science/article/pii/S2666379121002081) Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 25/07/2021 Summary Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody

Gretchen Vogel. Science  11 Jun 2021: DOI: 10.1126/science.372.6547.1138 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 23/07/2021 From combination studies support measures to stretch supplies, avoid side effects Science’s COVID-19 reporting is supported by the Heising-Simons Foundation Faced with short supplies of COVID-19 vaccines and unforeseen side effects,

Felten R, Kawka L, Dubois M, et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol 2021; published online July 21. https://doi.org/10.1016/S2665-9913(21)00221-6 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 23/07/2021 131 vaccine candidates have been evaluated for SARS-CoV-2

Jamie López Bernal  et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Inglés J Med. 2021 Jul 21. doi: 10.1056/NEJMoa2108891 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 22/07/2021 Resumen Antecedentes: La variante B.1.617.2 (delta) del coronavirus 2 del síndrome respiratorio agudo severo (SARS-CoV-2), el

DOI: 10.1056/NEJMc2108829 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 16/07/2021 AL EDITOR: Resumen Recientemente se han reportado datos provisionales de inmunogenicidad y eficacia para la vacuna Ad26.COV2.S (Johnson &&Johnson–Janssen) contra la enfermedad por coronavirus 2019 (Covid-19).1-3 Describimos aquí la durabilidad de 8 meses de inmunorespuestas humorales y

Robert W. Frenck et al. N Engl J Med 2021; 385:239-250 DOI: 10.1056/NEJMoa2107456 Recopilado por Carlos Cabrera Lozada. Director del postgrado de Medicina Materno Fetal. Universidad Central de Venezuela. ORCID: 0000-0002-3133-5183. 15/07/2021 Abstract BACKGROUND Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than